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Abstract
Objective Polymorphisms of the interleukin-23 receptor
(IL23R) gene have been found to play a role in the
development of several autoimmune diseases. Our aim was
to examine the possible effect of not only simple individual
variants, but of haplotypes composed of them.
Subjects We analysed 263 patients with psoriasis, 199
patients with Crohn’s disease (CD), 282 patients with ulcera-
tive colitis (UC), and 253 controls for rs1884444, rs11805303,
rs7517847, rs2201841, rs10889677 and rs11209032 variants.
Methods The genotypes were determined by using PCR/
RFLP assay. Logistic regression analysis was used to
compare the genotype distribution of the polymorphisms
and haplotypes between the examined autoimmune dis-
eases and healthy controls.
Results Rs1884444 was found to confer risk for UC and
psoriasis, rs10889677 for CD and psoriasis, while
rs2201841 and rs7517847 had effect only in CD. Using
these SNPs we could study the susceptibility haplotype
profiles in these diseases with special attention to UC.
Eight different haplotypes could be differentiated. We
found that the SNPs exert their susceptibility character in
specific haplotype blocks, and the frequency of one hap-
lotype differed significantly in UC compared with both
other diseases and also with healthy controls. This haplo-
type conferred risk for UC, even while it had a somewhat
lower frequency in the other diseases than in controls.
Conclusions The data presented here serve as evidence
for the need of haplotype analysis instead of just single
standing SNP analysis when susceptibility is interpreted.
Keywords IL23R  Ulcerative colitis  Crohn’s disease 
Psoriasis  IBD
Introduction
Interleukin-23 (IL-23) is a heterodimeric cytokine that
shows similar functions to IL-12 in promoting cellular
immunity and enhancing lymphocyte proliferation. How-
ever, unlike IL-12, IL-23 develops CD4? T cells into IL-17
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producing Th17 cells, instead of Th1 cells [1]. The Th17
cells produce several proinflammatory cytokines, like IL-
17, IL-6 and tumor necrosis factor (TNF-a) [2]. IL-23 is
recognized by its specific receptor-complex, IL23R. The
IL23R gene is located on chromosome 1p31, and the
encoded protein forms a receptor for IL23, together with
the b1 subunit of IL12 receptor (IL12Rb1) [3, 4]. These
two subunits compose the IL23R receptor-complex.
Crohn’s disease (CD) is a common form of inflamma-
tory bowel disease (IBD). CD is a chronic inflammation of
uncertain etiology, in which inflammation occurs primarily
in the ileum and colon, although any portion of the intes-
tinal tract can be affected. Ulcerative colitis (UC) is
another form of IBD that leads to chronic inflammation of
the digestive tract [5]. UC is restricted to the colon, char-
acteristically starting in the rectum and then spreading
proximally in a continuous fashion with mucosal ulcer-
ations [6]. The risk of colorectal cancer increases 2 % after
10 years, 8 % after 20 years, and 18 % after 30 years [7].
Psoriasis is a chronic inflammatory disease that affects the
skin and the joints. It is characterized by red, scaly skin
patches that appear mostly on the elbows, knees and scalp,
but can be present on any body surface and may be asso-
ciated with severe arthritis [8]. Prevalence rates vary from
0–5 % to 4–6 % between countries and races, affecting
2–3 % of whites of European descent [9]. The lesions are
caused by abnormal keratinocyte proliferation driven by
the activation of T lymphocytes, which leads to release of
cytokines.
IL23R polymorphisms were first associated with IBD
[10], and theoretical considerations immediately suggested
their role in other autoimmune and immune-mediated
diseases. In several cases, different research groups
obtained contradictory results in different populations
regarding the same disease. Moreover, it soon became clear
that not only the individual polymorphisms, but also the
haplotypes composed of them, can have significant effects.
Our research group found association of IL23R SNPs with
CD and psoriasis in a Hungarian population in former
studies [11, 12]. As the significance of the haplotype (ht)
analysis has already been revealed in previous studies in
relation with some diseases [13–15], in the current study
we performed comparative haplotype analysis of CD,
psoriasis, and with special attention to UC.
Materials and methods
The DNA samples of the control group and of the patients
with CD and ulcerative colitis originated from the central
Biobank governed by the University of Pe´cs, as part of the
National Biobank Network of Hungary (http://www.
biobank.hu), which belongs also to the pan-European
Biobanking and Biomolecular Resources Research Infra-
structure preparatory phase project (http://bbmri.eu/bbmri/).
The governance, maintenance and management principles of
the Biobank had been approved by the National Scientific
Research Ethics Committee, Budapest (ETT TUKEB). The
DNA samples of the patients with psoriasis were collected at
the Department of Dermatology and Allergology, University
of Szeged. During the entire investigation period, the guide-
lines and regulations of the 1975 Helsinki Declaration and the
currently operative national laws were followed; the patients
gave their informed consent for use of their collected, anon-
ymized DNA samples for research purposes.
We analysed a total of 263 psoriasis (126 males, 137
females), 199 CD (82 males, 117 females), 282 UC patients
(103 males, 179 females), and 253 control subjects (104
males, 149 females).
The molecular analyses were performed using DNA
extracted from peripheral blood leukocytes with a routine
salting out procedure. PCR–RFLP methods were applied to
test the alleles of the IL-23 receptor gene (GenBank
NM_144701, GeneID 149233), using the following for-
ward and reverse primers: 50-CAG TCT TTT CCT GCT
TCC AGA CAT-30 and 50-AAT AAA ATC ATA CTC
TTG CCA ATG GCC C-30 for rs1884444; 50-TCT TCC
CAG TCT CCA GTG TG-30 and 50-CCG AAC AAT TTT
TGT TTC CC-30 for rs11805303; 50-AAA CAT TGA CAT
TCC CTT CAT AC-30 and 50-GAA ATG AGT CAC CAA
TAA TCC AC-30 for rs7517847; 50-GGC AAA AGG GAA
TTG AGA GG-30 and 50-GGC CTA TGA TTA TGC TTT
TTC CTG-30 for rs2201841; 50-ATC GTG AAT GAG
GAG TTG CC-30 and 50-TGT GCC TGT ATG TGT GAC
CA-30 for rs10889677 and 50-TTG TTA CTG GAG TTA
AAC CTC TTG C-30 and 50-AGG AAT AAT TGC TGA
GAT GCA ATG-30 for rs11209032 alleles. For RFLP tests
PscI (rs1884444), MnlI (rs11805303 and rs10889677),
BseMII (rs7517847), HpyF3I (rs2201841) and BseMI
(rs11209032) restriction endonucleases were used, respec-
tively; each of the primer sets were designed to make an
obligate cleavage site on the amplicon to enable us to
control the efficacy of the digestion. The digestion of the
amplicon of rs1884444G resulted in 191 and 318 bp bands,
while the T allele was indicated by 28, 191 and 290 bp
digestion products. The rs11805303C allele resulted in 39,
136 and 198 bp fragments, and the T allele in 136 and 237
bp bands. The rs7517847T allele was characterized by
bands with 29, 91 and 410 bp, while for the G allele 29 and
501 bp digestion products could be detected. The
rs2201841T allele resulted in 163 and 257 bp fragments,
while the C allele in 25, 163 and 232 bp bands. For the
rs10889677C allele, the restriction endonuclease cleaves
the PCR product into 61, 185 and 224 bp fragments. If the
A allele was present, 185 and 285 bp fragments could be
detected. For the rs11209032G allele, the restriction
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endonuclease cleaves the PCR product into 24, 67 and 174
bp fragments. If the A allele was present 24 and 242 bp
fragments could be seen.
Associations of the diseases and the examined genetic
variants were tested using binary logistic regression anal-
ysis using SPSS 11.5 for Windows. Haploview 4.1 was
used to study linkage disequilibrium (LD) patterns. We
required the minor allele frequency at each locus to be[0.05,
with an R2 value of\0.8 between pairs of loci, based on the
default settings in Haploview. Haplotype frequencies were
estimated using PHASE version 2.1 [16, 17].
The allele composition of some frequent haplotypes is
shown in Table 1.
Results
The genotypes and minor allele frequencies (MAFs) of the
examined IL23R variants are shown in Table 2. The
rs1884444 SNP TT genotype showed a strong suscepti-
bility nature in UC patients (p = 0.001; OR = 3.13; 95 %
CI: 1.60–6.13) and in psoriasis patients (p = 0.005;
OR = 2.68; 95 % CI: 1.35–5.35) as well. The rs7517847
GG genotype has a protective effect against the develop-
ment of CD (p = 0.017; OR = 0.48; 95 % CI: 0.27–0.88),
while the rs2201841 and rs10889677 homozygous variants
confer risk for the disease (p = 0.007; OR = 2.43; 95 %
CI: 1.27–4.62 and p = 0.016; OR = 2.28; 95 % CI:
Table 1 Major haplotypes (ht)
of the examined IL23R variants
rs1884444 rs11805303 rs7517847 rs2201841 rs10889677 rs11209032
ht1 G C G T C G
ht2 G C T T C G
ht3 T T T C A A
ht4 T C T T C G
ht5 T C G T C G
ht6 G T T C A A
ht7 G C G T C A
ht8 T T T C A G
Table 2 Genotypes and minor
allele frequencies
* p \ 0.05 versus controls
CD (n = 199) UC (n = 282) Psoriasis (n = 263) Controls (n = 253)
rs1884444 GG 60 (30.2) 68 (24.1) 75 (28.5) 61 (24.1)
GT 133 (66.8) 176 (62.4) 157 (59.7) 180 (71.1)
TT 6 (3.00) 38 (13.5)* 31 (11.8)* 12 (4.74)
MAF 0.36 0.45 0.42 0.40
rs11805303 CC 80 (40.2) 135 (47.9) 111 (42.2) 129 (51.0)
CT 99 (49.7) 124 (44.0) 126 (47.9) 102 (40.3)
TT 20 (10.1) 23 (8.16) 26 (9.98) 22 (8.70)
MAF 0.35 0.30 0.34 0.29
rs7517847 TT 72 (36.2) 115 (40.8) 89 (33.8) 74 (29.2)
TG 110 (55.3) 122 (43.3) 128 (48.7) 138 (54.5)
GG 17 (8.54)* 45 (16.0) 46 (17.5) 41 (16.2)
MAF 0.36 0.38 0.42 0.43
rs2201841 TT 77 (38.7) 132 (46.8) 89 (33.8) 123 (48.6)
TC 94 (47.2) 129 (45.7) 128 (48.7) 114 (45.1)
CC 28 (14.1)* 21 (7.45) 46 (17.5) 16 (6.32)
MAF 0.38 0.30 0.42 0.29
rs10889677 CC 77 (38.7) 128 (45.4) 128 (48.5) 117 (46.2)
CA 97 (48.7) 133 (47.2) 106 (40.3) 121 (47.8)
AA 25 (12.6)* 21 (7.45) 29 (11.0)* 15 (5.93)
MAF 0.37 0.24 0.31 0.30
rs11209032 GG 69 (34.7) 134 (47.5) 127 (48.3) 109 (43.1)
GA 107 (53.8) 122 (43.3) 107 (40.7) 120 (47.4)
AA 23 (11.6) 26 (9.22) 29 (11.0) 24 (9.49)
MAF 0.38 0.31 0.31 0.33
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1.17–4.45, respectively). The later SNP is associated with
psoriasis also (p = 0.041; OR = 1.97; 95 % CI:
1.03–3.76).
Four haplotypes were associated with the examined
diseases; the major haplotype frequencies can be seen in
Table 3. A total of three haplotypes conferred risk for the
development of either of the examined diseases. Ht5
occurred significantly more frequently in UC than in
healthy controls (p = 0.003; OR = 2.50; 95 % CI:
1.36–4.58). Two haplotypes, ht6 and ht8, showed a strong
susceptibility effect for the development of CD, with ht6
showing the highest level of significance among all (for ht6
p \ 0.001; OR = 3.04; 95 % CI: 1.69–5.46 and for ht8
p = 0.020; OR = 2.62; 95 % CI: 1.16–5.89).
When the profile of the major haplotypes was studied,
several strongly significant differences between UC and
the other two examined diseases were verified (shown in
Table 3.). Ht5 was accumulated in UC compared to both
CD (p \ 0.001) and psoriasis (p = 0.045). Ht6 was
found less frequently in UC than in CD (p = 0.002),
while ht4 was, on the contrary, elevated in UC compared
to CD (p = 0.021). The frequency of ht6 also showed
a significant difference between psoriasis and CD
(p = 0.006).
Discussion
In the last few years the IL23R molecule and its variants
have been subjects of thorough investigation in autoim-
mune diseases. Its associations have been described with
several diseases, like IBD [10, 18–20], psoriasis [21, 22],
and AS [23–25], and have been studied also in Sjo¨gren
syndrome [24] and systemic lupus erythematosus [26, 27].
Very recently, a study of the association of IL23R haplo-
types with some of these diseases had also been initiated
[12, 28, 29].
Results concerning the role of IL23R SNPs in UC are
contradictory. Duerr et al. [10] were the first to report
association of the gene with UC. Soon after, a replication
study performed on Chilean IBD patients did not find any
association [30], while in Spanish patients, even though a
tendency could be observed, it did not reach the required
level of significance [31]. These observations prompted us
to investigate the effects of IL23R SNPs in a Hungarian
UC population and to carry out a haplotype analysis too.
We genotyped the same polymorphisms for CD, the other
form of IBD, and also for a distinct autoimmune disorder,
namely psoriasis, in which IL23R has been previously
shown to play an important role [12, 21, 22].
We detected an association with rs1884444 in UC and
psoriasis, however interestingly not in CD. Three major
haplotypes consisting of the six investigated SNPs showed
association with either of the studied diseases, and one
haplotype (ht5) only with UC—a fact which calls attention
to how different are the effects that haplotypes and single
polymorphisms can have.
During the analysis of our data, very different distribu-
tions of haplotypes in the three investigated diseases could
be identified. We found a statistically significant difference
between CD and psoriasis in the case of one haplotype, but
very interestingly, between the two forms of IBD, the
frequency of three haplotypes showed a significant differ-
ence. Ht5 was elevated in UC compared to all studied
populations. The elevation of ht6 frequency seems to be a
distinct marker for CD. These results underline not only the
different effects of individual SNPs and compound haplo-
types, but also how seemingly similar diseases can differ
from one another in the details of their genetic background.
The exact nature of how the haplotypes exert their effect
is still not known. For SNPs involving or directly affecting
coding regions, like the rs1884444 variant here, when the
G?T variant in position 94 associates with His?Gln,
there is usually strong effect on the helical structure of the
protein product that can be detected using different in vitro
approaches. Several roles in IL23R gene expression have
been attributed to the untranslated regions. The rs10889677
C?A change in position 2284 can affect mRNA stability,
mRNA localization, and translational efficiency. The
intronic variants of IL23R rs11805303 C?T change in
position 48348, rs7517847 T?G change in position 54501,
rs2201841 T?C change in position 67034 may influence
mRNA length and protein product. However, for other
allelic sites (like rs11209032 G?A) encoding no amino
acids in the intergenic region in haplotypes can modify
regulatory nucleic acid binding reactions, siRNA interac-
tions, and can have an influence on position effects. As
recent studies have identified, IL-23 is a key player in both
innate and adaptive immune systems, and most IL-23 is
secreted by activated dendritic cells, monocytes and
Table 3 Haplotype frequencies of the examined IL23R variants
CD (%) UC (%) Psoriasis (%) Controls (%)
ht1 21.1 21.0 24.7 24.7
ht2 19.9 20.1 17.0 17.4
ht3 12.8 15.1 14.3 12.9
ht4 5.50 9.47§ 9.33 8.42
ht5 4.83 9.72*,§,# 5.91 6.55
ht6 10.4* 6.14§ 6.71§ 4.99
ht7 2.32 1.27 1.68 2.44
ht8 3.62* 3.41 2.07 1.67
* p \ 0.05 compared to controls
§ p \ 0.05 compared to CD patients
# p \ 0.05 compared to psoriasis patients
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macrophages following their exposure to pathogen-derived
molecules that bind to toll-like receptors; moreover, IL-23
stimulates a unique CD4?helper T-cell population char-
acterized by the production of IL-17, tumor necrosis factor
and IL-6, known as Th17 cells; in this complex cascade of
events, several regulatory points can be supposed [32, 33].
As there are clinical and immunological differences and
concurrent overlaps in the diseases we investigated, com-
plex and even different actions can be supposed for the
individual haplotypic variants.
Taken together, the data presented here show how
important it is to study SNPs together, and not only the
separate SNPs themselves, since some effects can only be
detected this way, and it seems that some polymorphisms
tend to act only in specific blocks.
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